<unk>  (Urece) is a drug for the treatment of gout and hyperuricemia. It was developed by Fuji Yakuhin and approved for use in Japan in 2020. The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe.<unk>  acts as a selective urate reabsorption inhibitor that has uric acid lowering activity.
Dotinurad
Fermagate
Brodifacoum
Dimethyl methylphosphonate
Tricresyl phosphate
Photoanethole
Fenvalerate
Disufenton sodium